NCT00085774已完成3 期
A Single-Dose Efficacy Comparison of Albuterol Hydrofluoroalkane (HFA) Breath-operated Inhaler (BOI) (Volare Easi-Breathe™) and Albuterol HFA Meter Dose Inhaler (MDI) (Volare™) in Adolescents and Adults With Exercise-Induced Bronchospasm
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- The primary endpoint was mean maximum % change in the baseline absolute forced expiratory volume in 1 second (FEV1) value observed up to 1 hour post-challenge.
研究概览
简要总结
This study was designed to examine the effectiveness of two bronchodilator inhalers in patients who have exercise-induced asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent
- •Male or non-pregnant, non-nursing females aged 12 40 years, inclusive, at the first screening visit
- •Have exercise-induced bronchospasm (EIB), with or without asthma, as demonstrated by a ≥15% decrease in pre-challenge absolute FEV1 observed up to 60 minutes following an exercise challenge conducted at the first screening visit
- •Predicted FEV1 ≥70% for age, height, gender, and, where applicable, race following an 8 hour period without [beta]2 agonist use
- •Have no contraindications for exercising maximally
- •Ability to perform spirometry reproducibly (i.e., the difference between the two highest FEV1 values out of a minimum of three and a maximum of eight values obtained at the first screening visit must not exceed 0.2 L)
- •Ability to self-perform PEF (peak expiratory flow) determinations with a handheld peak flow meter
- •Can tolerate withdrawal of applicable medications for qualification at both screening visits
- •Normal chest X ray, or, if abnormal, is consistent with asthma and shows no evidence of other active disease
- •Otherwise healthy individuals with clinically acceptable medical history, physical examination, vital signs, and 12 lead ECG (electrocardiogram; with 30 second Lead II rhythm strip)
- •Body mass index (BMI) of 19 29 kg/m2 (BMI = weight [kg] / height2 [m])
- •Non-smokers for at least one year prior to the first screening visit and have maximum smoking histories of ten-pack years (i.e., equivalent to 20 cigarettes per day for 10 years).
排除标准
- •Allergy or sensitivity to albuterol or to other components of the formulations used in the drug
- •Exposure to investigational drugs within 30 days prior to the first screening visit
- •Require continuous treatment with [beta] blockers (administered by any route), MAO (monoamine oxidase) inhibitors, tricyclic antidepressants, cromones (by any route), antileukotrienes, and/or systemic corticosteroids
- •Treated with oral or injectable corticosteroids within the 12 weeks prior to the first screening visit
- •The prescribed dose regimen of any required inhaled corticosteroids has not been stable for at least four weeks prior to the first screening visit NOTE: Patients requiring subsequent dosage adjustment of these drug products must be discontinued from the study.
- •Inability to tolerate or unwillingness to comply with required washout periods for all applicable medications and xanthine-containing foods and beverages prior to the screening visit
- •Treatment in an emergency room for asthmatic symptoms or hospitalization for asthmatic symptoms within twelve months prior to the first screening visit
- •Experienced an upper respiratory tract infection and/or sinusitis associated with exacerbation of asthmatic symptoms not requiring emergency room treatment and/or hospitalization and/or treatment with oral or injected corticosteroids that has not resolved within four weeks prior to the screening visit
- •History and/or presence of any clinically-significant acute or chronic disease, including but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis, cystic fibrosis, clinically significant cardiovascular disease (including cardiac arrhythmias and uncontrolled hypertension), clinically significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes, hyperthyroidism, convulsive disorders, and neoplastic disease other than basal cell carcinoma of the skin
- •Known or suspected substance abuse (e.g., alcohol, marijuana, etc.) and/or presence of any other medical or psychological conditions that in the investigator's opinion should preclude study enrollment.
- •Are employees of this study site or have a family member associated with the conduct of this study at this site
- •Previous enrollment in an IVAX Research-sponsored Albuterol HFA aerosol asthma study.
研究组 & 干预措施
Albuterol HFA MDI
Experimental
干预措施: albuterol aerosol by HFA MDI (Drug)
Albuterol HFA BOI
Experimental
干预措施: albuterol aerosol by HFA BOI (Drug)
Placebo
Placebo Comparator
干预措施: placebo aerosol by HFA (Drug)
结局指标
主要结局
The primary endpoint was mean maximum % change in the baseline absolute forced expiratory volume in 1 second (FEV1) value observed up to 1 hour post-challenge.
时间窗: Three doses 2-7 days apart
次要结局
- Mean percent change in the baseline percent-predicted FEV1 value at each post-challenge time point(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Mean largest negative (or mean smallest positive) percent change in the baseline absolute FEV1 value observed up to one hour post-challenge(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Mean largest negative (or mean smallest positive) percent change in the average test-day pre-dose baseline percent predicted FEV1 value observed up to one hour post-challenge(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Time to recovery (in minutes) measured from time of completion of exercise challenge to time FEV1 returns to 10% or less of baseline value during the recovery phase(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Total changes in FEV1 expressed as the baseline-adjusted area-under-the-effect curve of the percent-predicted FEV1 versus time over 60 minutes (AUEC0 60)(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Percentage of patients who are "protected" (maximum percent decrease in the baseline absolute FEV1 <10%), "partially protected" (10 20%), and "unprotected" (>20%).(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Mean percent change in the baseline absolute FEV1 value at each post-challenge time point(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Mean absolute change in the baseline absolute FEV1 value at each post-challenge time point(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Mean maximum percent change in the baseline percent predicted FEV1 value observed up to one hour post-challenge(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
- Mean maximum absolute change in the baseline absolute FEV1 value observed up to one hour post-challenge(exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler TechniqueAsthmaNCT00054964Teva Branded Pharmaceutical Products R&D, Inc.14
已完成
2 期
Comparison of Two Bronchodilator Inhalers in Pediatric AsthmaticsAsthmaNCT00112411Teva Branded Pharmaceutical Products R&D, Inc.
已完成
4 期
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With AsthmaAsthmaNCT00530062Teva Branded Pharmaceutical Products R&D, Inc.49
已完成
4 期
Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPDCOPDNCT02576626Wouter H. van Geffen40
已完成
3 期
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference ProductAsthmaNCT02308098Orion Corporation, Orion Pharma72